Relevium Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 40.81%
- Profit Growth 133.26%
- Ebitda 59.93%
- Net Worth 14.71%
- Total Assets 90.70%
About Relevium Pharma
Relevium Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 June 2016 (Eight years and seven months 30 days old ). Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anant Bhagwat, Dnyaneshwar Patil, and Shankar Jadhav serve as directors at the Company.
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999MH2016PTC282810
- Company No.
282810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Relevium Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anant Bhagwat  | Director | 23-Jun-2016 | Current |
| Dnyaneshwar Patil | Director | 23-Jun-2016 | Current |
| Shankar Jadhav | Director | 15-Mar-2024 | Current |
Financial Performance of Relevium Pharma.
Relevium Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 40.81% increase. The company also saw a substantial improvement in profitability, with a 133.26% increase in profit. The company's net worth Soared by an impressive increase of 14.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Relevium Pharma?
Unlock access to Relevium Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Radhesham Edusocial FoundationAnant Bhagwat and Shankar Jadhav are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Relevium Pharma?
Unlock and access historical data on people associated with Relevium Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Relevium Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relevium Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
